Dexilant not an 'Innovative Drug' under Canada's Food and Drug Regulations: Majority of Federal Court of Appeal

Journal of Intellectual Property Law & Practice, Forthcoming

6 Pages Posted: 21 Feb 2013 Last revised: 24 Feb 2013

See all articles by Dr. Emir Crowne

Dr. Emir Crowne

New City Chambers

Lida Moazzam

University of Windsor - Faculty of Law

Date Written: February 20, 2013

Abstract

In Takeda Canada Inc. v. Canada (Health), 2013 FCA 13, a majority of the Federal Court of Appeal refused to list Takeda’s acid reflux drug, Dexilant, as an 'innovative drug' under Canada’s Food and Drug Regulations.

Keywords: data, protection, innovative, drug, pharma, Canada, Dexilant, NAFTA, TRIPS, Federal Court, FCA

Suggested Citation

Crowne, Emir and Moazzam, Lida, Dexilant not an 'Innovative Drug' under Canada's Food and Drug Regulations: Majority of Federal Court of Appeal (February 20, 2013). Journal of Intellectual Property Law & Practice, Forthcoming , Available at SSRN: https://ssrn.com/abstract=2221674

Emir Crowne (Contact Author)

New City Chambers

13 Fitzgerald Lane
Port-Of-Spain
Trinidad and Tobago

HOME PAGE: http://newcitychambers.com/

Lida Moazzam

University of Windsor - Faculty of Law ( email )

401 Sunset Avenue
Windsor, Ontario N9B 3P4 N9B 3P4
Canada

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
90
Abstract Views
714
Rank
513,029
PlumX Metrics